antimony has been researched along with Disease Models, Animal in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (26.32) | 18.7374 |
| 1990's | 4 (21.05) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 7 (36.84) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carregal, VM; Demicheli, C; Frézard, F; Fujiwara, RT; Islam, A; Lanza, JS; Rivas, L; Souza, DM | 1 |
| Almeida-Amaral, EE; Gervazoni, LFO; Gonçalves-Ozório, G | 1 |
| Cardoso, TN; Dalastra Laurenti, M; de Paula Coelho, C; Perez Hurtado, EC; Roberti Benites, N; Rodrigues de Santana, F; Villano Bonamin, L | 1 |
| Andrade, MS; Corrêa-Júnior, JD; Demicheli, C; Fernandes, FR; Ferreira, LA; Frézard, F; Lanza, JS; Magalhães-Paniago, R; Melo, MN; Vilela, JM | 1 |
| Almeida, RP; Cardoso, CR; Carregaro, V; Carvalho, EM; Costa, DL; de Jesus, AR; Giudice, Â; Lima-Júnior, DS; Milanezi, CM; Silva, JS; Silva, NM | 1 |
| Bhaumik, SK; De, T; Karmakar, S; Naskar, K; Paul, J | 1 |
| Das, AK; Dujardin, JC; Mukherjee, B; Mukherjee, S; Mukhopadhyay, R; Naskar, K; Roy, S; Sundar, S | 1 |
| Gómez, A; Henao, HH; Osorio, Y; Saravia, NG; Travi, B | 1 |
| Steck, EA | 1 |
| Hariprashad, J; Murray, HW; Rainey, PM; Roberts, WL | 1 |
| Astier, A; Bories, C; Deniau, M; Durand, R; Fusai, T; Houin, R; Paul, M; Rivollet, D | 1 |
| Hayes, RB | 1 |
| Delph-Etienne, S; Murray, HW | 1 |
| Anacleto, C; Andrade, AF; Ferreira, AV; Gazola, KC; Michalick, MS; Moreira, ES | 1 |
| Alving, CR; Chapman, WL; Hanson, WL; Hendricks, LD; Steck, EA; Swartz, GM; Waits, VB | 1 |
| Granger, AM; Mohanty, SK; Murray, HW | 1 |
| Hewitt, PJ; Hicks, R | 1 |
| Cheever, AW; Powers, KG | 1 |
| Gill, BS | 1 |
2 review(s) available for antimony and Disease Models, Animal
| Article | Year |
|---|---|
The chemotherapy of protozoal infections: whither?
Topics: Animals; Antimony; Antimony Sodium Gluconate; Antiprotozoal Agents; Disease Models, Animal; Glycolipids; Humans; Leishmaniasis; Leishmaniasis, Visceral; Liposomes; Lysosomes; Malaria; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Primaquine; Protozoan Infections; Trypanosomiasis | 1981 |
The carcinogenicity of metals in humans.
Topics: Animals; Antimony; Arsenic; Beryllium; Cadmium; Carcinogens; Chemical Industry; Chromium; Cobalt; Disease Models, Animal; Environmental Exposure; Humans; Industry; Lead; Lung Neoplasms; Metals; Neoplasms; Neoplasms, Experimental; Nickel; Nose Neoplasms; Occupational Exposure; Risk Factors; Solubility | 1997 |
17 other study(ies) available for antimony and Disease Models, Animal
| Article | Year |
|---|---|
Combination oral therapy against Leishmania amazonensis infection in BALB/c mice using nanoassemblies made from amphiphilic antimony(V) complex incorporating miltefosine.
Topics: Administration, Oral; Animals; Antimony; Antiprotozoal Agents; Disease Models, Animal; Female; Leishmania mexicana; Leishmaniasis, Cutaneous; Mice, Inbred BALB C; Nanoparticles; Phosphorylcholine | 2019 |
2'-Hydroxyflavanone activity in vitro and in vivo against wild-type and antimony-resistant Leishmania amazonensis.
Topics: Administration, Oral; Animals; Antimony; Antiprotozoal Agents; Disease Models, Animal; Drug Resistance; Female; Flavanones; Humans; Leishmania; Leishmaniasis, Cutaneous; Macrophages; Mice; Mice, Inbred BALB C; Parasite Load | 2018 |
Modulation of inflammation response to murine cutaneous Leishmaniasis by homeopathic medicines: Antimonium crudum 30cH.
Topics: Animals; Antimony; Brazil; Disease Models, Animal; Homeopathy; Inflammation; Leishmaniasis, Cutaneous; Lymph Nodes; Male; Mice; Mice, Inbred BALB C; Spleen | 2014 |
Polarity-sensitive nanocarrier for oral delivery of Sb(V) and treatment of cutaneous leishmaniasis.
Topics: Administration, Oral; Animals; Antimony; Antiprotozoal Agents; Disease Models, Animal; Drug Carriers; Female; Hydrophobic and Hydrophilic Interactions; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Mice, Inbred BALB C; Microscopy, Atomic Force; Nanoparticles; Organometallic Compounds; Scattering, Small Angle; Solvents; Treatment Outcome; X-Ray Diffraction | 2016 |
BALB/c mice infected with antimony treatment refractory isolate of Leishmania braziliensis present severe lesions due to IL-4 production.
Topics: Animals; Antimony; Antiprotozoal Agents; Brazil; Disease Models, Animal; Drug Resistance; Female; Humans; Interleukin-4; Leishmania braziliensis; Leishmaniasis, Cutaneous; Mice; Mice, Inbred BALB C; Rodent Diseases; Skin; Th1 Cells; Th2 Cells | 2011 |
Asiaticoside induces tumour-necrosis-factor-α-mediated nitric oxide production to cure experimental visceral leishmaniasis caused by antimony-susceptible and -resistant Leishmania donovani strains.
Topics: Animals; Antimony; Antiprotozoal Agents; Disease Models, Animal; Drug Resistance; Enzyme-Linked Immunosorbent Assay; Female; Leishmania donovani; Leishmaniasis, Visceral; Liver; Macrophages; Mice; Mice, Inbred BALB C; Microscopy; Nitric Oxide; Polymerase Chain Reaction; Spleen; Treatment Outcome; Triterpenes; Tumor Necrosis Factor-alpha | 2012 |
Imipramine is an orally active drug against both antimony sensitive and resistant Leishmania donovani clinical isolates in experimental infection.
Topics: Administration, Oral; Animals; Antimony; Antiprotozoal Agents; Cricetinae; Disease Models, Animal; Drug Resistance; Imipramine; Leishmania donovani; Leishmaniasis, Visceral; Parasitic Sensitivity Tests; Treatment Outcome | 2012 |
[Efficacy and toxicity of pentavalent antimonials (Glucantime and Pentostam) in an American cutaneous leishmaniasis animal model: luminometry application].
Topics: Animals; Antimony; Antimony Sodium Gluconate; Antiprotozoal Agents; Cricetinae; Disease Models, Animal; Leishmaniasis, Cutaneous; Meglumine; Meglumine Antimoniate; Organometallic Compounds | 2004 |
Pentavalent antimony-mannan conjugate therapy of experimental visceral leishmaniasis.
Topics: Animals; Antimony; Antimony Sodium Gluconate; Antiprotozoal Agents; Disease Models, Animal; Drug Carriers; Injections, Intraperitoneal; Leishmania donovani; Leishmaniasis, Visceral; Liver; Mannans; Mice; Mice, Inbred BALB C | 1996 |
Action of pentamidine-bound nanoparticles against Leishmania on an in vivo model.
Topics: Animals; Antimony; Antiprotozoal Agents; Colloids; Disease Models, Animal; Drug Carriers; Female; Leishmania major; Leishmaniasis, Visceral; Liver; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Microspheres; Organometallic Compounds; Pentamidine; Polymethacrylic Acids; Random Allocation | 1994 |
Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis.
Topics: Amphotericin B; Animals; Antimony; Antiprotozoal Agents; Disease Models, Animal; Enzyme Inhibitors; Female; Granulomatous Disease, Chronic; Guanidines; Interferon-gamma; Leishmaniasis, Visceral; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide Synthase; Nitric Oxide Synthase Type II | 2000 |
Cell surface carbohydrates and in vivo infectivity of glucantime-sensitive and resistant Leishmania (Viannia) guyjanensis cell lines.
Topics: Animals; Antimony; Antiprotozoal Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cricetinae; Disease Models, Animal; Drug Resistance; Glycosphingolipids; Lectins; Leishmania guyanensis; Leishmaniasis, Mucocutaneous; Male; Meglumine; Meglumine Antimoniate; Mesocricetus; Organometallic Compounds; Time Factors | 2001 |
Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs.
Topics: Animals; Antimony; Antimony Sodium Gluconate; Cricetinae; Disease Models, Animal; Gluconates; Leishmaniasis; Liposomes; Liver; Meglumine; Pharmaceutical Vehicles; Phospholipids; Structure-Activity Relationship; Surface Properties | 1978 |
Response to chemotherapy in experimental visceral leishmaniasis: T cell-dependent but interferon-gamma- and interleukin-2-independent.
Topics: Animals; Antibodies, Monoclonal; Antimony; Disease Models, Animal; Female; Interferon-gamma; Interleukin-2; Leishmaniasis, Visceral; Mice; Mice, Inbred BALB C; T-Lymphocytes | 1991 |
An investigation of the effects of inhaled welding fume in the rat.
Topics: Animals; Antimony; Atmosphere Exposure Chambers; Chromium; Cobalt; Disease Models, Animal; Environment, Controlled; Environmental Exposure; Iron; Lung; Male; Neutron Activation Analysis; Rats; Respiratory Tract Diseases; Welding | 1973 |
Rate of destruction of Schistosoma mansoni eggs and adult worms in the tissues of rhesus monkeys.
Topics: Animals; Antimony; Colon; Disease Models, Animal; Feces; Female; Haplorhini; Intestine, Small; Liver; Mice; Ovum; Parasite Egg Count; Schistosoma; Schistosomiasis; Succinates; Time Factors | 1971 |
Treatment of experimental Trypanosoma evansi infection of rodents with captostibone.
Topics: Animals; Antimony; Antiprotozoal Agents; Cattle; Cattle Diseases; Disease Models, Animal; Horse Diseases; Horses; Injections, Intraperitoneal; Mice; Rats; Sulfonic Acids; Tartrates; Trypanosomiasis | 1971 |